[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568375":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":51,"collaborators":10,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","OTHER",[8,12,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":10},"Group A",null,"Patients newly diagnosed with advanced EE starting active surveillance",{"label":13,"type":10,"description":14,"interventionNames":10},"Group B","Patients with new diagnosis of advanced, evolving EE, worthy of medical treatment",{"label":16,"type":10,"description":17,"interventionNames":10},"Group C","Patients with a previous diagnosis of advanced EE, already under active surveillance",{"label":19,"type":10,"description":20,"interventionNames":10},"Group D","Patients with a previous diagnosis of advanced EE with ongoing medical treatment",{"label":22,"type":10,"description":23,"interventionNames":10},"Group E","Patients with localized EHE",[25],{"name":26,"affiliation":5,"role":27},"Silvia Stacchiotti","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","0223902803","Silvia.Stacchiotti@istitutotumori.mi.it",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Fondazione IRCCS IstitutoNazionale dei Tumori","RECRUITING","Milan","20133","Italy",{"type":41,"coordinates":42},"Point",[43,44],9.18951,45.46427,{"lat":44,"lon":43},[47,48],{"name":26,"role":30,"phone":10,"phoneExt":10,"email":32},{"name":49,"role":30,"phone":10,"phoneExt":10,"email":50},"Anna Maria Frezza","annamaria.frezza@istitutotumori.mi.it",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100568375",false,"NCT06680401","Epithelioid Haemangioendothelioma Observational Study","The Evaluation of Cytokines and Hormones as Biomarkers for Epithelioid Haemangioendothelioma and Generation of Patient-derived Preclinical Models to Assess the Activity of Anticancer Agents and Validate Novel Therapeutic Targets","Inclusion Criteria:\n\n* Histological diagnosis of EHE according to 2020 WHO classification, performed on biopsy or surgical specimen\n* Signed informed consent\n* Adequate patient compliance to treatment or follow up\n* No age limit\n\nExclusion Criteria:\n\n* Impossibility to ensure adequate compliance","ALL","18 Years",{"count":62,"type":63},50,"ESTIMATED","OBSERVATIONAL","The EHE observational study was developed to obtain a high number of datas such as clinical presentation, natural history, and treatment outcomes, cto identificate cytokines and hormones as biomarkers and generate patient-derived preclinical models as a tool to assess the activity of anticancer agents and validate novel therapeutic targets",[67,68,69],"Clinical Presentation","Natural History","Treatment Outcomes","2026-03-27",{"date":72,"type":73},"2026-04-01","ACTUAL",{"date":75,"type":73},"2021-02-25",{"date":77,"type":63},"2028-12",{"name":5,"class":6},1]